Published in Women's Health Weekly, September 21st, 2000
A. de Gramont and colleagues at Hospital St. Antoine and IDM, Paris, and Erasme Hospital, Brussels, conducted a study "to assess the safety and the efficacy of intraperitoneal (i.p.) injections of monocyte-derived activated killer cells (MAK) mixed with anti-HER2/neu + anti-Fc gamma RI bispecific antibody on the residual disease (RD) of ovarian cancer after surgery and chemotherapy."
They presented study data at the 36th Annual Meeting of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.